azathioprine has been researched along with Scleroderma, Systemic in 58 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This suggests that treatment of pulmonary fibrosis in SSc with low-dose prednisolone and IV CYC followed by AZA stabilizes lung function in a subset of patients with the disease." | 9.12 | A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. ( Black, CM; Denton, CP; Desai, S; du Bois, RM; Ellis, RW; Emery, P; Foley, NM; Goh, NS; Herrick, AL; Hoyles, RK; Lees, B; McHugh, NJ; Newlands, P; Pearson, SB; Roberts, C; Veale, DJ; Wells, AU; Wellsbury, J, 2006) |
| " This suggests that treatment of pulmonary fibrosis in SSc with low-dose prednisolone and IV CYC followed by AZA stabilizes lung function in a subset of patients with the disease." | 5.12 | A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. ( Black, CM; Denton, CP; Desai, S; du Bois, RM; Ellis, RW; Emery, P; Foley, NM; Goh, NS; Herrick, AL; Hoyles, RK; Lees, B; McHugh, NJ; Newlands, P; Pearson, SB; Roberts, C; Veale, DJ; Wells, AU; Wellsbury, J, 2006) |
| " We report a case of a 70-year-old woman, who was diagnosed with diffuse cutaneous systemic sclerosis and psoriasis vulgaris and was treated with oral azathioprine (50 mg/d) and prednisolone (10 mg/d), topical corticosteroids, and calcipotriols." | 4.31 | Case of systemic sclerosis overlapping with psoriasis. ( Hua, X; Rao, L; Tan, H; Xie, Y; Zhou, P, 2023) |
| "Our patient with SSC-myositis overlap and severe dysphagia requiring PEG feeding, improved with high dose corticosteroids, azathioprine, two courses of IVIG and rituximab, and remained in remission 20 months after hospital discharge." | 3.85 | Recovery from severe dysphagia in systemic sclerosis - myositis overlap: a case report. ( Chinniah, KJ; Mody, GM, 2017) |
| " Patients were treated with azathioprine and low-dose prednisone if they had progressive pulmonary symptoms (deterioration in the dyspnea score) or poor or deteriorating lung function." | 3.72 | Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. ( Cassim, B; Dheda, K; Lalloo, UG; Mody, GM, 2004) |
| " During first 6 months of the trial, the patients also received prednisolone, which was started at a dosage of 15 mg daily and tapered to zero by the end of the sixth month." | 2.72 | A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. ( Davis, P; Fritzler, M; Kovalenko, W; Nadashkevich, O, 2006) |
| "Azathioprine (AZA) is an immunosuppressant commonly used for organ transplantation and autoimmune diseases." | 2.42 | Drug eruption caused by azathioprine: value of using the drug-induced lymphocytes stimulation test for diagnosis. ( Hakamada, A; Isoda, K; Kaketa, M; Mizutani, H; Mori, H; Tamada, K; Yamanaka, K; Yamanishi, K, 2004) |
| "European data indicate that systemic sclerosis (SSc)-related death rates are increasing, thus raising concerns about SSc's optimal management." | 1.56 | Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. ( Bertsias, G; Boumpas, D; Bournia, VK; Chatzidionysiou, Κ; Daoussis, D; Dimitroulas, T; Drosos, AA; Garyfallos, Α; Georgiopoulos, G; Liossis, SC; Panopoulos, S; Sakkas, L; Sfikakis, PP; Sidiropoulos, P; Tektonidou, MG; Thomas, K; Vassilopoulos, D; Vosvotekas, G; Voulgari, PV, 2020) |
| "Forty-nine patients affected by systemic sclerosis (44 women and five men, mean age 52." | 1.35 | Cyclophosphamide treatment improves microvessel damage in systemic sclerosis. ( Bambara, LM; Biasi, D; Caramaschi, P; Mahamid, H; Pieropan, S; Tinazzi, I; Volpe, A, 2009) |
| "Primary systemic sclerosis (PSS) is such a disease characterised by multi-organ fibrosis." | 1.35 | Graves' disease associated with primary systemic sclerosis. ( Wimmersberger, Y; Zuercher, D, 2009) |
| " The mean dosage of azathioprin and prednisone in patients with SLE did not significantly differ from the non-SLE group." | 1.27 | [Reactivation of the alpha 1-fetoprotein synthesis in systemic lupus erythematosus]. ( Knopf, B; Schulze, M; Wollina, U, 1985) |
| "A female patient showed signs of osteomyelofibrosis after being treated for 70 months." | 1.26 | [Progressive systemic sclerosis - long-term treatment with azathioprin (author's transl)]. ( Jäckle, B; Maas, D; Raif, W; Schramm, A; Schubothe, H, 1979) |
| "All but one of 28 patients with mixed connective tissue disease (MCTD) who were studied prospectively had arthralgia, and 15 of them had noticed joint swelling." | 1.26 | Articular manifestations of mixed connective tissue disease. ( Alarcón-Segovia, D; Hernández-Ortíz, J; Ramos-Niembro, F, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (44.83) | 18.7374 |
| 1990's | 6 (10.34) | 18.2507 |
| 2000's | 13 (22.41) | 29.6817 |
| 2010's | 8 (13.79) | 24.3611 |
| 2020's | 5 (8.62) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, Y | 1 |
| Hua, X | 1 |
| Tan, H | 1 |
| Rao, L | 1 |
| Zhou, P | 1 |
| Jelovac, M | 1 |
| Kotur, N | 1 |
| Ristivojevic, B | 1 |
| Pavlovic, D | 1 |
| Spasovski, V | 1 |
| Damjanov, N | 1 |
| Pavlovic, S | 1 |
| Zukic, B | 1 |
| Panopoulos, S | 1 |
| Chatzidionysiou, Κ | 1 |
| Tektonidou, MG | 1 |
| Bournia, VK | 1 |
| Drosos, AA | 1 |
| Liossis, SC | 1 |
| Dimitroulas, T | 1 |
| Sakkas, L | 1 |
| Boumpas, D | 1 |
| Voulgari, PV | 1 |
| Daoussis, D | 1 |
| Thomas, K | 1 |
| Georgiopoulos, G | 1 |
| Vosvotekas, G | 1 |
| Garyfallos, Α | 1 |
| Sidiropoulos, P | 1 |
| Bertsias, G | 1 |
| Vassilopoulos, D | 1 |
| Sfikakis, PP | 1 |
| Kiboshi, T | 1 |
| Kotani, T | 1 |
| Konma, J | 1 |
| Makino, H | 1 |
| Matsuda, S | 1 |
| Suzuka, T | 1 |
| Wada, Y | 1 |
| Shiba, H | 1 |
| Hata, K | 1 |
| Shoda, T | 1 |
| Takeuchi, T | 1 |
| Chinniah, KJ | 1 |
| Mody, GM | 2 |
| Zheng, JN | 1 |
| Yang, QR | 1 |
| Zhu, GQ | 1 |
| Pan, L | 1 |
| Xia, JX | 1 |
| Wang, Q | 1 |
| Cappelli, S | 1 |
| Bellando-Randone, S | 1 |
| Guiducci, S | 1 |
| Matucci-Cerinic, M | 1 |
| Poormoghim, H | 1 |
| Rezaei, N | 1 |
| Sheidaie, Z | 1 |
| Almasi, AR | 1 |
| Moradi-Lakeh, M | 1 |
| Almasi, S | 1 |
| Andalib, E | 1 |
| Iudici, M | 1 |
| Cuomo, G | 1 |
| Vettori, S | 1 |
| Bocchino, M | 1 |
| Sanduzzi Zamparelli, A | 1 |
| Cappabianca, S | 1 |
| Valentini, G | 1 |
| Goh, KG | 1 |
| Ong, SG | 1 |
| Robles-Perez, A | 1 |
| Molina-Molina, M | 1 |
| Caramaschi, P | 1 |
| Volpe, A | 1 |
| Pieropan, S | 1 |
| Tinazzi, I | 1 |
| Mahamid, H | 1 |
| Bambara, LM | 1 |
| Biasi, D | 1 |
| Quillinan, NP | 1 |
| Denton, CP | 2 |
| Wimmersberger, Y | 1 |
| Zuercher, D | 1 |
| Bussone, G | 1 |
| Mouthon, L | 2 |
| Chan, PT | 1 |
| Mok, CC | 1 |
| Dheda, K | 1 |
| Lalloo, UG | 1 |
| Cassim, B | 1 |
| Jacobi, AM | 1 |
| Feist, E | 1 |
| Rudolph, B | 1 |
| Burmester, GR | 1 |
| Mori, H | 1 |
| Yamanaka, K | 1 |
| Kaketa, M | 1 |
| Tamada, K | 1 |
| Hakamada, A | 1 |
| Isoda, K | 1 |
| Yamanishi, K | 1 |
| Mizutani, H | 1 |
| Nadashkevich, O | 1 |
| Davis, P | 1 |
| Fritzler, M | 1 |
| Kovalenko, W | 1 |
| Hoyles, RK | 1 |
| Ellis, RW | 1 |
| Wellsbury, J | 1 |
| Lees, B | 1 |
| Newlands, P | 1 |
| Goh, NS | 1 |
| Roberts, C | 1 |
| Desai, S | 1 |
| Herrick, AL | 1 |
| McHugh, NJ | 1 |
| Foley, NM | 1 |
| Pearson, SB | 1 |
| Emery, P | 1 |
| Veale, DJ | 1 |
| Wells, AU | 1 |
| Black, CM | 1 |
| du Bois, RM | 1 |
| Scheja, A | 1 |
| Hesselstrand, R | 1 |
| Wildt, M | 1 |
| Akesson, A | 1 |
| Domysławska, I | 1 |
| Ciołkiewicz, M | 1 |
| Kowal-Bielecka, O | 1 |
| Lewszuk, A | 1 |
| Klimiuk, PA | 1 |
| Sierakowski, S | 1 |
| Bérezné, A | 1 |
| Ranque, B | 1 |
| Valeyre, D | 1 |
| Brauner, M | 1 |
| Allanore, Y | 1 |
| Launay, D | 1 |
| Le Guern, V | 1 |
| Kahn, JE | 1 |
| Couderc, LJ | 1 |
| Constans, J | 1 |
| Cohen, P | 1 |
| Mahr, A | 1 |
| Pagnoux, C | 1 |
| Hachulla, E | 1 |
| Kahan, A | 1 |
| Cabane, J | 1 |
| Guillevin, L | 1 |
| Choy, E | 1 |
| Kingsley, G | 1 |
| Panayi, G | 1 |
| Bottomley, WW | 1 |
| Sheehan-Dare, RA | 1 |
| Hughes, P | 1 |
| Cunliffe, WJ | 1 |
| Komócsi, A | 1 |
| Kumánovics, G | 1 |
| Zibotics, H | 1 |
| Czirják, L | 1 |
| Hellmich, B | 1 |
| Schnabel, A | 1 |
| Bauer, T | 1 |
| Schatz, H | 1 |
| Pirofsky, B | 1 |
| Bardana, EJ | 1 |
| Schulze, P | 1 |
| Alexander, M | 1 |
| Kampf, D | 1 |
| Kurwa, AR | 1 |
| Denman, AM | 1 |
| Maas, D | 1 |
| Schramm, A | 1 |
| Jäckle, B | 1 |
| Raif, W | 1 |
| Schubothe, H | 1 |
| Ramos-Niembro, F | 1 |
| Alarcón-Segovia, D | 1 |
| Hernández-Ortíz, J | 1 |
| Faust, G | 1 |
| Zöller, B | 1 |
| Brinkrolf, H | 1 |
| Yamada, H | 1 |
| Ogawa, H | 1 |
| Sönnichsen, N | 1 |
| Brenke, A | 2 |
| Ruiz, JC | 1 |
| Val, F | 1 |
| de Francisco, AL | 1 |
| de Bonis, E | 1 |
| Zubimendi, JA | 1 |
| Prieto, M | 1 |
| Canga, E | 1 |
| Sanz de Castro, S | 1 |
| Arias, M | 1 |
| Witt, C | 1 |
| Neuhaus, K | 1 |
| Winsel, K | 1 |
| Hiepe, F | 1 |
| Volk, HD | 1 |
| Wollina, U | 1 |
| Schulze, M | 1 |
| Knopf, B | 1 |
| Laaff, H | 1 |
| Balle, C | 1 |
| Schön, S | 1 |
| Freudenberg, N | 1 |
| Schollmeyer, P | 1 |
| Peter, HH | 1 |
| Hällgren, R | 1 |
| Svenson, K | 1 |
| Johansson, E | 1 |
| Lindh, U | 1 |
| Götzel, L | 1 |
| Wüthrich, B | 1 |
| Delespesse, G | 1 |
| Kennes, B | 1 |
| Duchateau, J | 1 |
| Moeschlin, S | 1 |
| Klein, G | 2 |
| Fellner, S | 1 |
| Fellner, R | 1 |
| Skinner, MD | 1 |
| Schwartz, RS | 1 |
| Kerl, H | 1 |
| Sandhofer, M | 1 |
| Saporta, L | 1 |
| Godeau, P | 1 |
| Delrieu, F | 1 |
| Delbarre, F | 1 |
| Rosenthal, DS | 1 |
| Sack, B | 1 |
| Califano, A | 1 |
| Cainelli, T | 1 |
| Ghislanzoni, G | 1 |
| Kostanecki, W | 1 |
| Mazurkiewicz, W | 1 |
| Górkiewicz, A | 1 |
| Zborzil, J | 1 |
| Cruchaud, A | 1 |
| Schuppli, R | 2 |
| Thivolet, J | 1 |
| Perrot, H | 1 |
| Jansen, GT | 1 |
| Barraza, DF | 1 |
| Ballard, JL | 1 |
| Honeycutt, WM | 1 |
| Dillaha, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease[NCT01862926] | Phase 2/Phase 3 | 104 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| A Randomized Controlled Trial to Compare the Efficacy of Oral Mycophenolate Mofetil With Placebo in Patients With Systemic Sclerosis Related Early Interstitial Lung Disease[NCT02896205] | Phase 3 | 41 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for azathioprine and Scleroderma, Systemic
| Article | Year |
|---|---|
Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis?
Topics: Azathioprine; Biological Products; Cyclophosphamide; Humans; Immunosuppressive Agents; Methotrexate; | 2014 |
Treatment Considerations of Lung Involvement in Rheumatologic Disease.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Cyclophosphamide | 2015 |
Disease-modifying treatment in systemic sclerosis: current status.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantigens; Azathioprine; Collagen | 2009 |
Interstitial lung disease in systemic sclerosis.
Topics: Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Azathioprine; Contraindications; Cyclophosph | 2011 |
Pauci-immune crescentic glomerulonephritis in limited cutaneous systemic sclerosis.
Topics: Antibodies, Antineutrophil Cytoplasmic; Antirheumatic Agents; Azathioprine; Biopsy; Cyclophosphamide | 2012 |
Drug eruption caused by azathioprine: value of using the drug-induced lymphocytes stimulation test for diagnosis.
Topics: Azathioprine; Diagnosis, Differential; Drug Eruptions; Female; Humans; Immunosuppressive Agents; Lym | 2004 |
Immunosuppressive therapy in rheumatic disease.
Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Dermatomyositis; Gr | 1977 |
[Indications and limits of long-term therapy with immunosuppressive (and cytostatic) agents in various chronic skin diseases].
Topics: Arthritis, Reactive; Azathioprine; Chronic Disease; Cyclophosphamide; Dermatomyositis; Humans; Immun | 1977 |
[Immunovasculitis-- differential diagnosis and therapy of inflammatory systemic diseases].
Topics: Adult; Angiography; Arthritis, Rheumatoid; Autoimmune Diseases; Azathioprine; Diagnosis, Differentia | 1976 |
[Auto-immune diseases and immunodepressive therapy. II. Current clinical indications].
Topics: Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Arteritis; Autoimmune | 1974 |
Immunosuppressive therapy. 1.
Topics: Alkylating Agents; Anemia, Hemolytic, Autoimmune; Antibodies; Antimetabolites; Arthritis, Rheumatoid | 1972 |
5 trials available for azathioprine and Scleroderma, Systemic
| Article | Year |
|---|---|
A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis.
Topics: Administration, Oral; Adult; Aged; Azathioprine; Cyclophosphamide; Female; Humans; Immunosuppressive | 2006 |
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Azathioprine; Cyclophosphamide; Double-Blind Method; | 2006 |
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Azathioprine; Cyclophosphamide; Double-Blind Method; | 2006 |
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Azathioprine; Cyclophosphamide; Double-Blind Method; | 2006 |
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Azathioprine; Cyclophosphamide; Double-Blind Method; | 2006 |
Immunosuppressive therapy in rheumatic disease.
Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Dermatomyositis; Gr | 1977 |
[Indomethacin in rheumatic diseases with special reference to ophthalmologic studies].
Topics: Allopurinol; Arthritis, Rheumatoid; Azathioprine; Blood Cells; Capsules; Clinical Trials as Topic; E | 1972 |
Immunosuppressive therapy. 1.
Topics: Alkylating Agents; Anemia, Hemolytic, Autoimmune; Antibodies; Antimetabolites; Arthritis, Rheumatoid | 1972 |
44 other studies available for azathioprine and Scleroderma, Systemic
| Article | Year |
|---|---|
Case of systemic sclerosis overlapping with psoriasis.
Topics: Aged; Azathioprine; Female; Humans; Prednisolone; Psoriasis; Scleroderma, Diffuse; Scleroderma, Syst | 2023 |
Can Pharmacogenetic Variants in
Topics: Azathioprine; Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Methotrexate; Methylenet | 2023 |
Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort.
Topics: Adult; Aged; Azathioprine; Cohort Studies; Cyclophosphamide; Endothelin Receptor Antagonists; Female | 2020 |
Comparison of therapeutic effects of combination therapy with prednisolone and tacrolimus or azathioprine on progressive interstitial pneumonia with systemic sclerosis.
Topics: Azathioprine; Drug Therapy, Combination; Fibrosis; Humans; Immunosuppressive Agents; Lung Diseases, | 2022 |
Recovery from severe dysphagia in systemic sclerosis - myositis overlap: a case report.
Topics: Adrenal Cortex Hormones; Azathioprine; Cyclophosphamide; Deglutition Disorders; Drug Therapy, Combin | 2017 |
Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis.
Topics: Adult; Azathioprine; Bayes Theorem; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Lung | 2020 |
Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study.
Topics: Administration, Oral; Adult; Aged; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female | 2014 |
Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
Topics: Adult; Azathioprine; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 2015 |
Recurrent spontaneous subdural hematoma secondary to immune thrombocytopenia in a patient with overlap syndrome.
Topics: Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Female; Hematoma, Subdural; Humans; Immuno | 2015 |
Cyclophosphamide treatment improves microvessel damage in systemic sclerosis.
Topics: Aged; Azathioprine; Cyclophosphamide; Female; Humans; Immune System; Immunosuppressive Agents; Infla | 2009 |
Graves' disease associated with primary systemic sclerosis.
Topics: Azathioprine; Bosentan; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Graves | 2009 |
Experience with azathioprine in systemic sclerosis associated with interstitial lung disease.
Topics: Azathioprine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspnea; Female; Glucocor | 2004 |
Sinusoidal dilatation: a rare side effect of azathioprine.
Topics: Azathioprine; Dilatation, Pathologic; Female; Humans; Immunosuppressive Agents; Liver; Liver Cirrhos | 2004 |
Relapse of skin thickening after discontinuation or decrease of azathioprine therapy in a patient with diffuse cutaneous systemic sclerosis.
Topics: Aged; Azathioprine; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2007 |
[Coexistence of scleroderma-like syndrome and idiopathic myelofibrosis in a 54-year-old female patient: case report].
Topics: Antineoplastic Agents; Azathioprine; Female; Glucocorticoids; Humans; Hydroxyurea; Immunosuppressive | 2007 |
Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
Topics: Administration, Oral; Adult; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Drug Therapy, Com | 2008 |
Systemic sclerosis occurring in a patient with Adamantiades-Behçet's disease.
Topics: Azathioprine; Behcet Syndrome; Female; Humans; Immunosuppression Therapy; Middle Aged; Scleroderma, | 1993 |
A sclerodermatous syndrome with unusual features following prolonged occupational exposure to organic solvents.
Topics: Azathioprine; Chemical Industry; Humans; Male; Middle Aged; Occupational Diseases; Prednisolone; Scl | 1993 |
Alveolitis may persist during treatment that sufficiently controls muscle inflammation in myositis.
Topics: Adult; Aged; Azathioprine; Bronchoalveolar Lavage Fluid; Dermatomyositis; Drug Therapy, Combination; | 2001 |
[Interstitial pulmonary disease in systemic scleroderma: treatment].
Topics: Azathioprine; Cytokines; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Immunosup | 2002 |
[Hyperergic collagenoses. Clinical aspects, differential diagnosis and therapy (author's transl)].
Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Child; Collagen Diseases; Cyclophosphamide; Derm | 1977 |
Scleroderma treated with immunosuppressive drugs.
Topics: Antilymphocyte Serum; Azathioprine; Female; Humans; Immunosuppressive Agents; Middle Aged; Prednisol | 1979 |
[Progressive systemic sclerosis - long-term treatment with azathioprin (author's transl)].
Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Azathioprine; Female; Humans; Male; Middle Aged; P | 1979 |
Articular manifestations of mixed connective tissue disease.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Arthritis, Rheumatoid; Azathioprine; Child; Female; Huma | 1979 |
[Plasma exchange therapy of dermatosis].
Topics: Adult; Aged; Aged, 80 and over; Azathioprine; Betamethasone; Female; Humans; Middle Aged; Pemphigoid | 1992 |
[Therapeutic possibilities in systemic scleroderma].
Topics: Antibodies, Antinuclear; Autoantibodies; Azathioprine; Combined Modality Therapy; Dose-Response Rela | 1992 |
Progressive systemic sclerosis and renal transplantation: a contraindication to the use of cyclosporine A?
Topics: Azathioprine; Contraindications; Cyclosporins; Drug Therapy, Combination; Female; Humans; Kidney; Ki | 1991 |
[Bronchoalveolar lavage in patients with systemic scleroderma and systemic lupus erythematosus: characterization of cell activity by cytofluorometry, chemiluminescence and differential cell count].
Topics: Adult; Azathioprine; B-Lymphocyte Subsets; Bronchoalveolar Lavage Fluid; Female; Flow Cytometry; Hum | 1991 |
[Reactivation of the alpha 1-fetoprotein synthesis in systemic lupus erythematosus].
Topics: Alanine Transaminase; alpha-Fetoproteins; Antibodies; Arthritis, Rheumatoid; Aspartate Aminotransfer | 1985 |
[Rapid decrease in renal function (scleroderma renal crisis) in progressive systemic sclerosis treated with immunosuppressive agents].
Topics: Adult; Azathioprine; Female; Humans; Kidney Failure, Chronic; Kidney Function Tests; Middle Aged; Pr | 1988 |
Abnormal calcium and magnesium stores in erythrocytes and granulocytes from patients with inflammatory connective tissue diseases. Relationship to inflammatory activity and effect of corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Azathioprine; Calcium; Cyclophosphamide; | 1985 |
[Complications of immunosuppressive therapy using cytostatics in autoaggression diseases with special reference to cholestatic hepatosis].
Topics: Adrenal Cortex Hormones; Autoimmune Diseases; Azathioprine; Chemical and Drug Induced Liver Injury; | 1973 |
[Treatment of scleroderma].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Antimalarials; Azathioprine; Dextrans; Edetic | 1973 |
[Treatment of autoimmune diseases].
Topics: Adrenal Cortex Hormones; Aged; Anemia, Hemolytic, Autoimmune; Antilymphocyte Serum; Autoimmune Disea | 1971 |
[Treatment of "collagen and autoimmune" diseases (author's transl)].
Topics: Adolescent; Adult; Aminobenzoates; Azathioprine; Chloroquine; Cyclophosphamide; Dermatomyositis; Dex | 1973 |
[Generalized scleroderma. Treatment with immunosuppressive agents].
Topics: Adult; Azathioprine; Chlorambucil; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Male; | 1972 |
Autoimmune hemolytic anemia in scleroderma.
Topics: Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Azathioprine; Clinical Enzyme Tests; Coombs | 1971 |
[1st data on the immunosuppressive therapy of scleroderma].
Topics: Adolescent; Adult; Azathioprine; Child; Female; Humans; Male; Middle Aged; Scleroderma, Systemic | 1971 |
[Hair changes in immunosuppressive therapy].
Topics: Antineoplastic Agents; Azathioprine; Chlorambucil; Cyclophosphamide; Hair; Humans; Immunosuppression | 1971 |
[Immunosuppressive treatment of collagen diseases].
Topics: Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Collagen Diseases; Cyclophosphamide; Dermatomyosi | 1969 |
[Practical use of immunosuppressive and cytostatic drugs in dermatological diseases].
Topics: Antineoplastic Agents; Azathioprine; Condylomata Acuminata; Fluorouracil; Humans; Immunosuppressive | 1970 |
[Treatment of dermatologic lesions using immunosuppressive agents and cytostatics].
Topics: Antineoplastic Agents; Azathioprine; Dermatomyositis; Fluorouracil; Humans; Immunosuppressive Agents | 1970 |
[So-called immunosuppressive cytotoxic medication in acute disseminated lupus erythematosus and scleroderma].
Topics: Acute Disease; Adult; Azathioprine; Cyclophosphamide; Female; Glucocorticoids; Humans; Immunosuppres | 1970 |
Generalized scleroderma. Treatment with an immunosuppressive agent.
Topics: Adult; Aged; Azathioprine; Blood Sedimentation; Child; Female; Humans; Latex Fixation Tests; Male; M | 1968 |